Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • University of Michigan • NCI-CCC Lymphoma Tumor Board Question
How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?
Answer from: at Community Practice
It goes without saying this is a “data-free zone.” I would consider extrapolating from CLL and adding venetoclax.
Sign in or Register to read more